Back to News & Events

Traverse Biosciences Announces Issuance of U.S. Patent

Traverse Biosciences has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,187,406 entitled, “Curcumin Analogues as Zinc Chelators and Their Uses,” which the company has exclusively licensed from the Research Foundation for the State University of New York (RF/SUNY). The issued patent includes claims that cover the composition of matter of the company’s proprietary library of chemically-modified curcumins, including its lead drug candidate, TRB-N0224.
Read more on the Traverse Biosciences website.

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2036 [post_author] => 3 [post_date] => 2016-03-22 18:51:09 [post_date_gmt] => 2016-03-22 18:51:09 [post_content] => Center for Biotechnology Director and Stony Brook Biomedical Engineering Chair Dr. Clinton Rubin recently spoke with Innovate Long Island about commercialization and entrepreneurship. A serial inventor, Dr. Rubin has been involved in three startup companies based on his technology which have all taught him different lessons about commercialization. As he notes in the article, “There’s a chasm between launching a technology and creating a company”. Read the full article here. [post_title] => “Even Research Needs a Rolodex” [post_excerpt] => Center for Biotechnology Director and Stony Brook Biomedical Engineering Chair Dr. Clinton Rubin recently spoke with Innovate Long Island about commercialization and entrepreneurship. A serial inventor, Dr. Rubin has been involved in three startup companies based on his technology which have all taught him different lessons about commercialization. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => even-research-needs-a-rolodex [to_ping] => [pinged] => [post_modified] => 2016-04-11 14:12:37 [post_modified_gmt] => 2016-04-11 14:12:37 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2036 [menu_order] => 186 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2881 [post_author] => 1 [post_date] => 2017-12-01 14:37:07 [post_date_gmt] => 2017-12-01 14:37:07 [post_content] => Just released: MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, a new book authored by Harry Glorkian & Malorye Allison Branca From Amazon.com: "How can a smartwatch help patients with diabetes manage their disease? Why can’t patients find out prices for surgeries and other procedures before they happen? How can researchers speed up the decade-long process of drug development? How will "Precision Medicine" impact patient care outside of cancer? What can doctors, hospitals, and health systems do to ensure they are maximizing high-value care? How can healthcare entrepreneurs find success in this data-driven market? A revolution is transforming the $10 trillion healthcare landscape, promising greater transparency, improved efficiency, and new ways of delivering care. This new landscape presents tremendous opportunity for those who are ready to embrace the data-driven reality. Having the right data and knowing how to use it will be the key to success in the healthcare market in the future. We are already starting to see the impacts in drug development, precision medicine, and how patients with rare diseases are diagnosed and treated. Startups are launched every week to fill an unmet need and address the current problems in the healthcare system. Digital devices and artificial intelligence are helping doctors do their jobs faster and with more accuracy. MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, which includes interviews with dozens of healthcare leaders, describes the business challenges and opportunities arising for those working in one of the most vibrant sectors of the world’s economy. Doctors, hospital administrators, health information technology directors, and entrepreneurs need to adapt to the changes effecting healthcare today in order to succeed in the new, cost-conscious and value-based environment of the future. The authors map out many of the changes taking place, describe how they are impacting everyone from patients to researchers to insurers, and outline some predictions for the healthcare industry in the years to come." [post_title] => MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market [post_excerpt] => MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, which includes interviews with dozens of healthcare leaders, describes the business challenges and opportunities arising for those working in one of the most vibrant sectors of the world’s economy. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => moneyball-medicine-thriving-in-the-new-data-driven-healthcare-market [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:38:51 [post_modified_gmt] => 2018-01-23 14:38:51 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2881 [menu_order] => 134 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3110 [post_author] => 3 [post_date] => 2018-12-18 16:29:30 [post_date_gmt] => 2018-12-18 16:29:30 [post_content] => As we all know, outside capital is like oxygen for technology related companies. Looking to raise funds to build your company? Equity crowdfunding may be an attractive option for startups or even companies of significant size (including those who have already done some capital raising!) Join the Center for Biotechnology, Farrell Fritz, P.C.and the Long Island High Technology Incubator for a workshop led by Alon Kapen, JD, Partner at Farrell Fritz, P.C. and Chair of its Emerging Companies and Venture Capital practice group. Mr. Kapen will discuss different types of equity crowdfunding available and key considerations for companies contemplating a crowdfunding offering. Topics will include costs, benefits, and drawbacks of different types of crowdfunding, including accredited crowdfunding under Rule 506(c) of Regulation D; non-accredited crowdfunding under Title III of the JOBS Act and Regulation Crowdfunding; and “mini” public offerings under “Regulation A+”. Thursday, February 7, 2019 | 9am-10am Long Island High Technology Incubator Main Conference Room. 25 Health Sciences Drive, Stony Brook, NY 11790 Registration is free – please RSVP here. https://cfb-equity-crowdfunding19.eventbrite.com   About our speaker: Mr. Kapen has extensive experience in providing focused representation to founders, startups, emerging companies, angel investors and venture capital funds in a wide range of high growth entrepreneurial matters and transactions. Farrell Fritz is a full service law firm of more than 85 attorneys that has earned a strong reputation in the New York business community. The firm handles legal matters in the areas of bankruptcy & restructuring; business divorce; commercial litigation; condemnation & eminent domain; construction; corporate & finance; distressed assets; eDiscovery; emerging companies & venture capital; environmental law; estate litigation; health law; labor & employment; land use, municipal & zoning; real estate; tax planning & controversy; tax certiorari and trusts & estates for corporations, not-for-profit organizations and individuals. The Long Island High Technology Incubator (LIHTI) is a non-profit organization dedicated to helping new technologically-innovative companies grow by providing them with a variety of support resources and services. Since its opening in 1992, the Incubator has been associated with more than 120 businesses, and over 60 companies have graduated successfully from the LIHTI program, contributing over $2.5B to the national economy and creating jobs for over 500 employees. Our affiliation with the Stony Brook University makes LIHTI an ideal place for cutting-edge R&D. Transferring technology and ideas from the University to the private sector has proven to be the single most important reason why the program has succeeded beyond anyone’s imagination.   [post_title] => EQUITY CROWDFUNDING WORKSHOP [post_excerpt] => Outside capital is like oxygen for technology related companies and equity crowdfunding may be attractive for companies from startup to a significant size - learn more at our workshop on January 11th. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => equity-crowdfunding-workshop [to_ping] => [pinged] => [post_modified] => 2019-04-09 14:41:13 [post_modified_gmt] => 2019-04-09 14:41:13 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3110 [menu_order] => 106 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

“Even Research Needs a Rolodex”

More Information

MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

More Information

EQUITY CROWDFUNDING WORKSHOP

More Information